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Abstract
Parkinson’s disease is the second most common neurodegenerative disease that negatively affects many American lives. It is 
characterized by the degeneration of dopamine-secreting neurons in the Substantia Nigra Pars Compacta (SNpc). Individuals 
with Parkinson’s Disease lack motor coordination and experience severe motor impairments. Unfortunately, there is currently 
no treatment method available that can successfully cure the disease. In fact, all of the mainstream available treatments only 
eliminate some PD symptoms, and they cause many negative side effects. Although nontraditional, exercise is a side effect free 
treatment method that can potentially slow the progression of the disease and alleviate some symptoms.  This paper first gives a 
comprehensive overview of the pathology and current treatments of Parkinson’s disease.  Then this paper reviews the benefits of 
exercise therapy for PD patients and the potential biological mechanisms that drive the success of exercise therapy.
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Introduction
Although not as prevalent as Alzheimers, Parkinsons disease(PD) 
is the second most common age-related neurodegenerative dis-
order (Paillard, et. al. 2015, Maiti, et. al. 2017). It occurs in about 
1-2% of the population over 65 and has been found to occur 
even less in younger populations (Maiti, et. al. 2017). Thus, age 
is considered to be one of the most prevalent risk factors for 
the development of the disease. Although Parkinson’s disease 
does affect multiple parts of the brain, it is mainly character-
ized as a neurodegenerative disease that causes the degradation 
of dopaminergic neurons located in the Substantia Nigra Pars 
Compacta (SNpc) (Maiti, et. al.  2017, et. al.  2013). In a healthy 
person, the axons of these neurons extend to the Striatum 
where they help relay inhibitory signals by secreting dopamine 
which in return causes the basal ganglia to send inhibitory sig-
nals to Globus Pallidus and thalamus. These inhibitory signals 
help regulate movement by preventing the thalamus from over 
stimulating the motor cortex and causing impairment of motor 
coordination (Maiti, et. al.  2017). Due to the degradation of 
SNpc neurons, patients with Parkinson’s disease have a signifi-
cant decrease of dopamine secretion in the Striatum and as a 
result they experience significant motor impairments (Petzinger, 
et. al. 2013, Maiti, et. al.  2017). 
Symptoms
PD is a neurodegenerative disorder that slowly worsens over 
time, thus, individuals with Parkinson disease experience a wider 
array of symptoms as the disease progresses. It takes around 15 to 
20 years for PD symptoms to progress and it is estimated that the 
first visible symptom is seen only once 80% of the SNcp neurons 
have died out. Due to the progressive nature of the disease, early 
symptoms are subtle and often unidentifiable (Sveinbjornsdottir, 
2016, Maiti, et. al.  2017). At first, most individuals will experience 
twitching in their arm, leg, jaw, lips or chin (Maiti, et. al. 2017). 
This symptom is called a resting tremor and is observed in the 
early stages of the disease in about 70% of PD patients (Maiti, et. 
al. 2017) (Moustafa, et al., 2016). It is most commonly found in 
the arms and the legs, and it usually starts off only on one side 
of the body. Gradually, this tremor develops bilaterally affecting 
both sides of the body (Maiti, Manna, & Dunbar, 2017). The second 
most common symptom is rigidity or stiffness of the muscles and 
joints (Maiti, et. al. 2017) (Moustafa, et al., 2016). This side effect 
causes individuals with PD to feel week and have severe cramping 
pain (Maiti, et. al. 2017). Individuals with PD also lose their ability 
to move quickly and experience a symptom called bradykinesia 
(Moustafa, et al., 2016, Maiti, et. al. 2017). Bradykinesia is char-
acterized by loss of automatic movements, slow handwriting, 
decreased eye blinking, lower speech volume, difficulty initiating 
movement and difficulty in stopping continuous movements. In 
addition, PD patients also experience balance and coordination 
problems and will often fall. All of the above symptoms are con-
sidered to be primary symptoms of Parkinson’s Disease and are 
essential for the diagnoses of the disease (Sveinbjornsdottir, 2016, 
Maiti, et. al.  2017). 
In addition to the above symptoms ,some secondary symptoms 
may develop. These include continued changes in speech including 
the slurring of words, the repetition of words and excessively 
slow or abnormally fast speech. Urination and defecation become 
exceedingly hard due to the slow movement of smooth mus-
cle in the digestive tract. Swallowing and chewing food becomes 
very difficult because of the bodies inability to perform peristalsis 
properly.  In addition, PD patients often have a hard time staying 
asleep at night due to “insomnia, Rem sleep behavior disorder, 
sleep apnea, sleep attacks and restless leg syndrome (Maiti, et. al. 
2017).” Some people with PD also experience depression, mood 
problems, anxiety, cognitive dysfunction, apathy and Dementia 
(Chauduri & Schapira, 2009) (Maiti, et. al. 2017). 
Mechanisms of Parkinson’s Disease
Parkinson’s Disease can manifest due to external factors or as a 
result of inherited genetic mutations. Most cases of PD are con-
sidered to be non-genetic forms of PD, that result from envi-
ronmental stimuli (Maiti, Manna, & Dunbar, 2017).  Both genetic 
forms and sporadic forms of PD follow similar mechanisms of 
neuronal degeneration.  Three of the most probable pathways 
of neuronal degeneration are death through mitochondrial 
dysfunction, A-synuclein aggregation, malfunctioning chaperone 
proteins and Autophagy lysosomal pathway damage.  
Mitochondrial dysfunction can be caused by both genetic and 
environmental factors. Some environmental factors that cause 
PD include pesticides, herbicides, fungicides, and insecticides. 
Consequently, farmers and individuals who live in rural areas 
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are considered to be more susceptible to PD due to direct ex-
posure to these substances through the air and drinking water. 
Other environmental factors that cause PD included bacterial 
toxins, viruses and illegal street drugs such as synthetic forms 
of heroin and rotenone. These environmental factors “inhib-
it complex one activity and cause dysfunction in the electron 
transport chain which causes oxidative stress (Maiti, et.al. 2017, 
p. 12).”  Gene mutations of the DJ-1 and Pink 1 genes also cause 
mitochondrial dysfunction that can result in oxidative stress by 
inhibiting the formation of mitochondrial protective proteins. 
Once initiated by either environmental or genetic factors, oxi-
dative stress causes the phosphorylation of tau proteins which 
eventually aggregate to form Lewy Bodies. These Lewy bodies 
accumulate in the cell making it exceedingly hard for the cell to 
complete basic tasks needed for neuronal function . Lewy bod-
ies also make pores in the cell membrane resulting in “neuro-
nal death via oxidative stress, energy failure, excitotoxicity, and 
neuronal inflammation. Eventually, the infected neurons begin to 
die due to their inability to perform tasks essential for survival”. 
In addition to oxidative stress, mitochondrial dysfunction can 
also directly lead to energy failure. Energy failure refers to the 
cells inability to produce the chemical energy needed for cell 
survival. Energy failure causes the degeneration and death of 
dopaminergic neurons (Maiti, Manna, & Dunbar, 2017). 
Mutations in the a-synuclein gene cause an alternative mech-
anism of neuronal degeneration. This mutation leads to the 
creation of misfolded α-synuclein proteins that eventually ag-
gregate and develop into Lewy Bodies .   Lewy bodies block up 
the cell making it close to impossible for basic cell functions to 
be completed. In addition, the Lewy bodies can make holes in 
the cell membrane which cause cell death by initiating, oxida-
tive stress, energy failure, excitotoxicity, and neuroinflammation 
(Maiti, et. al. 2017).  Thus, the α-synuclein gene mutation directly 
affects neuronal cell death. 
Mutations of the parkin and UCHL1 genes can lead to the 
death of SNpc neurons by causing the destruction of ubiqui-
tin-proteasome system(UPS) and molecular chaperones (Maiti, 
Manna, & Dunbar, 2017). The UPS actively brakes down short 
polypeptides into intracellular plasma membrane proteins, and 
it also helps with degeneration of “misfolded or damaged pro-
teins in the cytosol, nucleus or endoplasmic reticulum (Maitiet. 
Al. 2017, p. 9).”  Chaperone proteins play an important role in 
ensuring that proteins are folded properly. Damage to these 
two systems lead to the accumulation of misfolded proteins and 
to the impairment of the Autophagy Lysosomal pathway(ALP). 
The ALP helps degrade large protein debris that cannot be de-
graded by the UPS. When the UPS, chaperone proteins and ALP 
fail to complete their respective jobs, misfolded proteins begin 
to aggregate in the cell and form Lewy bodies (Maiti, Manna, & 
Dunbar, 2017). The Lewy bodies go on to disrupt cell function 
leading to the degeneration SNpc neurons. 
The Spread of the Disease
Many researchers believe that once Parkinson’s disease is initiat-
ed, Lewy body infected neurons transmit the disease to adjacent 
uninfected neurons (Maiti, Manna, & Dunbar, 2017). This method 
of proliferation is known as the prion hypothesis. Interestingly, 
many studies have found that α-synuclein begins to aggregate 
in the enteroendocrine cells of the gastrointestinal tract and 
then spreads to the brain via prion infection. Although this may 
be the method of proliferation used in some cases of PD, it is 
definitely not used in all PD cases since Lewy bodies are not 
necessary for initiation of PD (Maiti, et. al. 2017). 
Inflammation may also be responsible for the spread of 
Parkinson’s disease (Zhang, et al., 2011) (Phania, et. al. 2012). 
Neuronal inflammation occurs due to head trauma or the de-
velopment of pathogenic disease such as PD. Inflammation in the 
PD brain is characterized by activated microglia cells, astrocyte 
cells and imported T-cells that crossed the blood-brain barrier 
(Cebrián & Sulzer, 2017). In the case of Parkinson’s disease, the 
immune response is unbalanced, and instead of eliminating the 
disease it aids in the progression of the disease.  
Microglia cells are activated as a result of α-synuclein accu-
mulation (Cebrián & Sulzer, 2017). Once activated they act as 
phagocytic cells and participate in the removal of toxins and 
dead neurons (Vivekanantham, et al., 2015). They also produce 
“a plethora of pro-inflammatory mediators including prosta-
glandins, cytokines, chemokines, complement, proteinases, ROSs 
and RNSs (Vivekanantham, et al., 2015).” These substances ini-
tiate cell death by directly causing oxidative stress. In addition, 
microglia phagocytose extracellular neuromelanin that was re-
leased by dying neurons (Cebrián & Sulzer, 2017). During this 
process cytokines and hydrogen peroxide are released and cell 
death via oxidative stress is initiated (Zhang, et al., 2011).  
Astrocytes are supposed to help regulate the immune re-
sponse by protecting neurons from oxidative stress. In theory 
this would allow the microglia cells to participate in the immune 
responses without initiating neuronal cell death. However, be-
cause Parkinson’s disease affects a part of the brain that has 
almost no astrocytes, this regulatory system fails to occur. In 
addition, many of the astrocytes present in the PD brain contain 
α-synuclein aggregations and release harmful substances such 
as cytokines, chemokines, and IFN-T (Cebrián & Sulzer, 2017). 
Thus, although astrocytes have the potential to be neuroprotec-
tive in Parkinson’s disease, they are neurodestructive. 
In addition to the damage that both astrocytes and microglia 
cells cause independently, they also work together to proliferate 
the disease by increasing the permeability of the blood-brain 
barrier. They accomplish this task by releasing cytokines which 
actively increase the permeability of the blood-brain barrier. This 
allows CD4 T cells and CD8 T cells to enter the central nervous 
system easily. Once the T cells reach the SNcp, they are acti-
vated by microglia cells that present antigens on their surfaces 
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using MHC II molecules and MHC I molecules (Kannarkat, Boss, 
& Tansey, 2013). This activation causes the release of more cy-
tokines which leads to cytotoxicity and further activation of 
microglia cells (Kannarkat, et. al. 2013, Federoff, 2014). Thus, 
infiltrating T cells aid in the progression of Parkinson’s disease 
(Phania, et. al. 2012). 
Treatment
Traditional treatment for Parkinson’s disease is limited to medi-
cations, surgeries, stem cell implantation and gene therapies that 
are only effective in eliminating side effects and cannot cure 
the disease. Most of these treatment methods have a multitude 
of side effects and only work for a limited amount of time or 
on a small population of Parkinson’s patients.  Various tratmen-
toptions and their success in treating PD are reviewed below 
with a particular focus on their success in treating PD and their 
adverse side effects.
Medications
Levodopa, a precursor form of dopamine, is perhaps the most 
common PD medication (Connolly & Lang, 2014)  because it 
can cross the blood-brain barrier where it is converted to do-
pamine.  By increasing dopamine levels in the brain, this medi-
cation successfully reduces resting tremors (Maiti, et. al. 2017). 
Unfortunately, Levodopa has also been found to cause vomit-
ing, nausea, restlessness, drowsiness, low blood pressure, sud-
den onset of sleep and impulsive control disorders (Connolly 
& Lang, 2014) (Maiti, et. al. 2017). Additionally, chronic use of 
levodopa results in dyskinesia and motor fluctuations (Smith, et. 
al. 2012).  Levodopa also has been found to quickly lose its effec-
tiveness because it is converted immediately upon arrival into 
the central nervous system and by the time it reaches the target 
area enzymes have already started breaking it down (Maiti, et. 
al.  2017).  Thus, to increase the potency of levodopa, many do-
pamine agonists are administered in combination with levodopa. 
Monoamine oxidase-B (MAO-B) inhibitors such as selegiline 
and rasagiline are examples of dopamine agonists that are used 
in combination with levodopa (Maiti, et. al. 2017). MAO-B is an 
enzyme that participates in the breakdown of dopamine (Kay 
et. al. 2013). MAO-B inhibitors help prevent the breakdown of 
dopamine and increase the potency of levodopa (Smith, et. al. 
2012) (Maiti, et. al.  2017). Although these medications have been 
successful in prolonging the effects of levodopa, they also cause 
a multitude of negative side effects. Which include, “Dizziness, 
dry mouth, insomnia, muscle pain, rash, nausea, constipation, 
severe headache, tachycardia, arrhythmia, hallucinations, chorea, 
or difficulty in breathing (Maiti, Manna, & Dunbar, 2017, p. 19).” 
Another commonly used dopamine agonist is Catechol-O- 
methyltransferase (COMT) inhibitors (Maiti, Manna, & Dunbar, 
2017). These drugs prevent the breakdown of dopamine and 
increase the efficiency of levodopa (Smith, Wichmann, Factor, & 
DeLong, 2012) (Maiti, Manna, & Dunbar, 2017). Entacapone and 
tolcapone are two examples of commonly used COMT inhibitors 
(Smith, Wichmann, Factor, & DeLong, 2012). Along with increasing 
the lifespan of dopamine these drugs cause hepatotoxic, nausea, 
orthostatic hypotension, urine discoloration, dizziness and mito-
chondrial dysfunction (Maiti, Manna, & Dunbar, 2017).
Dopamine agonists such as pramipexole and ropinirole are 
examples of drugs that are used instead of levodopa to treat the 
early stages of Parkinson’s disease. They help alleviate Parkinson’s 
symptoms by increasing dopamine levels in the brain. These drugs 
are not as effective as levodopa, and they cause similar side effects 
as levodopa. Some of the side effects commonly observed while 
administering these drugs are hallucinations, low blood pressure, 
nausea, dizziness, drowsiness, dry mouth, swollen legs and feeling 
faint upon standing (Maiti, et. al.  2017). 
Anticholinergic drugs are also used to treat Parkinson’s dis-
ease. These drugs inhibit the release of acetylcholine, which 
is overproduced in the brains of Parkinson’s patients due to 
diminished dopamine inhibitory signaling (Maiti, et. al.  2017). 
They are successful in alleviating tremor and rigidity in about 
50% of patients (Smith, et. al.  2012) (Maiti, et. al. 2017). Their 
adverse side effects include memory loss, confusion, hallucina-
tions, constipation, urination problems, dry mouth, dry eyes and 
blurred vision (Smith, et. al. 2012). Due to the limited population 
that can be helped with anticholinergic drugs and the adverse 
side effects of these drugs they are less commonly used for the 
treatment of PD. 
Surgical Treatments
Deep brain stimulation(DBS) surgery is a common surgery used 
to treat the advanced stages of Parkinson’s disease. This surgery 
is only performed once all the medications mentioned above 
begin to lose their potency (Smith, et. al. 2012). Additionally, this 
surgery can only be performed on individuals who had success 
in using levodopa and show no signs of dementia or psychiatric 
abnormalities (Smith, et. al. 2012) (Okun, 2012). During DBS 
surgery electrodes are implanted into GPi and STN of the brain 
(Okun, 2012) (Maiti, et. al. 2017). These electrodes are attached 
to two batteries that are implanted in the chest directly under 
the color bone (Maiti, et. al. 2017).  Electrical signals are then 
generated by the implanted batteries and sent to the electrodes 
in the brain where they stimulate inactive neurons (Okun, 2012) 
(Maiti, et. al. 2017). Once implanted this device is controlled by 
an external handheld device (Maiti, et. al.  2017). DBS has been 
shown to successfully eliminate many motor abnormalities in-
cluding motor fluctuations. Additionally, because DBS eliminates 
the need for levodopa it successfully reduces dyskinesia and 
dystonia (Smith, et. al. 2012) (Maiti, et. al.  2017).  Unfortunately, 
DBS entails a surgery that can cause stroke, hemorrhage, infec-
tion, speech issues and balance problems (Okun, 2012) (Maiti, 
et. al.  2017) (Smith, et. al. 2012).  DBS has also been found to 
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increase depression, mania and suicide risk (Okun, 2012). Thus, 
although DBS can be helpful in treating PD, it may also cause 
adverse symptoms that can lead to death. 
Another two surgeries which are used to treat Parkinson’s 
disease are pallidotomy and thalamotomy. Pallidotomy is a sur-
gery in which a part of the globus pallidus is destroyed . As a 
result of this destruction, “the synaptic connections with thal-
amus or striatum are altered in a way which decreases tremor, 
rigidity, bradykinesia and posture abnormalities in PD patients 
(Maiti, et. al. 2017, p. 21).” Thalamotomy is the destruction of the 
thalamus, which disrupts the connection between the basal gan-
glia and the motor cortex. This procedure restores neurotrans-
mitter balance and reduces tremor . However, thalamotomy is 
unsuccessful in alleviating other symptoms such as bradykinesia, 
rigidity, and dyskinesias (Maiti, et. al. 2017).  
Stem Cell Implantation
Stem cell implantation therapy involves the implantation of 
human fetal-derived dopaminergic tissues into the striatum. 
Implantation of these tissues into the brain results in higher 
levels of dopamine, which indicates that these stem cells mature 
properly and are able to create synapses. When porcine-derived 
dopamine-producing cells are used moderate improvements in 
symptom control are observed. However, when allogenic human 
fetal ventral mesencephalic cells are used much greater symp-
tom relief is observed (Maiti, et. al. 2017). “These cells survive 
and make appropriate synaptic connections, while increasing DA 
levels within the host cells (Maiti, et. al.  2017, p. 22).”  Although 
stem cell implantation seems promising, it causes many safety is-
sues including unchecked proliferation and tumor development 
(Smith, et. al. 2012). Thus, more research is needed to develop 
this treatment technique and increase its safety.
Gene Therapy
Although most cases of Parkinson’s disease are sporadic, there 
are some genetic forms of the disease. Scientists are now start-
ing to develop gene therapy techniques that can cure the genet-
ic forms of PD. Some of the techniques that are being tested are 
viral vector-mediated gene delivery, AADC-TH -GCH therapy,  
RNA interference-based therapy and CRISR-Cas-9 gene editing 
system. Most of these therapies have been successful in animal 
models, and some have also been used to treat humans success-
fully. However, most of these therapies must be tested further 
in order to ensure their safety (Maiti, Manna, & Dunbar, 2017).
Exercise as a Treatment Method for PD
There is no treatment method for Parkinson’s disease that is 
symptom-free. In fact, all of the treatments available for PD are 
not successful at curing the disease, and when used they gener-
ate adverse side effects. Thus, Patients diagnosed with Parkinson’s 
disease often feel helpless and experience depression because 
until recently, their diagnosis meant awaiting and experiencing the 
impending uncontrollable loss of movement until death. 
However, in the past two decades, athletic programs such as 
Boxing, Tai Chi, dancing, treadmill training and forced bicycling 
have begun to bring hope to Parkinson’s patients. These programs 
are designed in a way that teaches Parkinson’s patients physical 
skills that helps stop the progression of the disease and even al-
lows some individuals to regain full range of movement. Studies 
have proven the success of these programs, but there is no sig-
nificant scientific work that can explain how exercise alleviates 
Parkinson’s symptoms on a biological level. In the past couple of 
years, scientists have turned their attention to discovering the un-
derlying biological mechanism that allows the above exercise pro-
grams to be so successful in treating Parkinson’s disease. Based 
on the current scientific research the most probable mechanisms 
are that exercise promotes neuroplasticity and neuroprotection. 
The Two Main Components that make an 
Exercise Program Successful
Most of the Successful exercise programs incorporate goal 
based learning and aerobic exercise. The inclusion of these two 
components helps promote neuroplasticity, which is defined as, 
 A process by which the brain encodes experiences and learns 
new behaviors… the modification of existing neural networks 
by addition or modification of synapses in response to chang-
es in behavior or environment, which can encompass exercise. 
Neuroplasticity includes a wide range of structural and phys-
iological mechanisms including synaptogenesis, neurogenesis, 
neuronal sprouting, and potentiation of synaptic strength, all of 
which can lead to the strengthening, repair, or formation of neu-
ronal circuitry (Petzinger, Fisher, McEwen, Beeler, & Walsh, 2013).
Goal-based learning refers to the incorporation of tasks that 
are aimed at improving specific skills that are impaired in PD. 
Intensity, specificity, complexity, repetition, and difficulty are all 
important aspects of goal-based exercise that help drive. Goal-
based exercise also stimulates cognitive engagement of the 
prefrontal cognitive circuits. These circuits are involved in early 
motor movement and the development of automaticity. Thus, 
activation of prefrontal circuits helps patients with Parkinson’s 
disease relearn skills that were previously automatic. Aerobic 
exercises are similar to goal-based exercise in the fact that 
it too promotes cognitive engagement and neuroplasticity. 
“Aerobic exercise is defined as vigorous and sustained physical 
activity that leads to increased cardiopulmonary function result-
ing in improved oxygen consumption (maximum oxygen uptake) 
and blood flow to the brain (Petzinger, et. al. 2013, p. 719).” By 
increasing blood flow to the brain, aerobic exercise stimulates 
neuroplasticity and improves cognitive prefrontal cortex func-
tion. When goal based and aerobic exercise are combined their 
effects are compounded, and significant changes in neuroplasti-
city are observed (Petzinger, et. al. 2013). 
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The Successful Programs and how they Incorporate 
Goal Based Learning and Aerobic Exercise
“Tai Chi, as a mind-body exercise, consists of a series of dance-
like movements linked in a continuous sequence, flowing slowly 
and smoothly from one movement to another that emphasizes 
weight transfer and movement of the body.” (Yan Yang, 2015, 
p. 2) It has been shown to improve dynamic postural control, 
balance, gait, and quality of life (Petzinger, et. al. 2013, Yan Yang, 
2015). In one study, scientists observed improved stride length, 
stability and maximum excursion in patients who had partici-
pated in tai chi classes twice a week for 24 weeks (Petzinger, 
Fisher, McEwen, Beeler, & Walsh, 2013). Tai chi incorporates cog-
nitive engagement by practicing combinations of movements 
and control of an individual’s center of gravity (Yan Yang, 2015). 
However, it does not include intense aerobic exercise, and it 
is not clear if this lowers its success rate compared to other 
exercise debilitation programs.  
Dance is an aerobic form of exercise that has also shown 
promise as a potential treatment for Parkinson’s Disease. 
Dance enhances motor learning by making people pay atten-
tion to music and rhythm (Blandy, Beevers, Kerry, & Morris, 
2015) (Petzinger, Fisher, McEwen, Beeler, & Walsh, 2013). In 
addition, partner dancing further stimulates cognitive engage-
ment by teaching people partner coordination (Petzinger, Fisher, 
McEwen, Beeler, & Walsh, 2013). By incorporating both cog-
nitive and aerobic exercise, dance has been found to improve 
gait, motor impairment and balance (Blandy, Beevers, Kerry, & 
Morris, 2015).  
Boxing therapy has become a very popular form of exer-
cise therapy for PD in the past couple of years. In 2006 The 
Rocksteady boxing foundation located in Indiana opened the 
first noncontact boxing program for PD Patients. Since then, 
Rocksteady boxing programs have been established across the 
United States. Boxing therapy takes a whole-body approach by 
including dynamic balance activities and multi-directional reach-
ing and stepping. These programs also include jump rope and 
framework activities that help improve people’s ability to initi-
ate movement (Combs, et al., 2011). Boxing helps improve bal-
ance, gait, parkinsonian symptoms and quality of life (Combs, et 
al., 2011) (Petzinger, et. al. 2013).  Scientists have reported that 
the benefits of boxing last for a long time even if patients stop 
participating in as many classes as they originally did. The boxing 
programs included aerobic exercise and goal-based exercise 
by incorporating fast-paced multi-directional body movement 
(Combs, et al., 2011). Thus, boxing is one of the most promising 
forms of exercise therapy available for PD patients. 
Cycling training is another popular form of exercise rehabili-
tation. Both forced cycling and voluntary cycling programs have 
been found to help improve PD symptoms (Nadeau, et al., 2017). 
In forced cycling PD patients are placed on an electric bike and 
forced to pedal at a speed that is above their comfort level 
(Ridgel, et. al.  2009). This system helps recruit cognitive involve-
ment and has been shown to improve neuroplasticity in the 
human brain. In addition, forced cycling helps improve tremor 
and bradykinesia. Voluntary cycling has been shown to improve 
cardiovascular capacity, executive function, motor learning and 
walking speed (Nadeau, et al., 2017). Both voluntary and forced 
cycling are promising treatment options for Parkinson’s Disease, 
and scientist still have not determined which form of cycling is 
more successful.
Treadmill training, when used to treat mild to moderate PD, 
helps improve, “velocity, postural stability, gait rhythmicity and 
joint excursion (Petzinger, Fisher, McEwen, Beeler, & Walsh, 
2013, p. 717).” Some studies have reported treadmill training to 
be completely infective at treating Parkinson’s disease. This in-
consistency may be a result of improper feedback during work-
outs, which is supposed to promote cognitive engagement and 
enhance motor learning (Petzinger, et. al. 2013). Thus, treadmill 
training is a prime example of an exercise program that must 
include both goal based and aerobic exercise in order to be 
effective.
Neuroprotection
Neuroprotection is the driving force behind the neuroplastic 
effects that both goal based and aerobic exercise exert on the 
PD brain. Exercise provides neuroprotection by increasing do-
pamine release and dopamine receptor expression, decreasing 
dopamine clearance from the synaptic terminals, stimulating the 
release of neuroprotective factors and initiating an anti-inflam-
matory response. 
Exercise therapy promotes the release of dopamine, decreas-
es dopamine clearance from the synaptic cleft and facilitates the 
binding of dopamine to D2 receptors in the dorsal striatum. 
Exercise has been found to increase dopamine synthesis and re-
lease in both human and mice models (Horak & King, 2009). One 
theory for how this is accomplished is that exercise increases 
tyrosine hydroxylase (TH) levels in the PD brain. TH is an en-
zyme that increases dopamine levels by converting L-tyrosine 
to L-dopa (a precursor form of dopamine) (Morgan, Corrigan, 
& Baune, 2015). TH has also been found to decrease aggregat-
ed a-synuclein proteins, which play a primary role in neuronal 
death in PD (Petzinger, Fisher, McEwen, Beeler, & Walsh, 2013). 
In addition, exercise decreases DAT levels, which participates in 
the degradation of dopamine in the synaptic clefts. This increas-
es the dopamine available to bind to dopamine receptors. D2 
receptors in the Putman are activated with intensive exercise 
and are available to bind to dopamine (Jakowec, Wang, et. al. 
2016). D2 receptors play an important role in cortical-striatal 
glutamatergic modulation and are essential for motor learning 
(Jakowec, et. al. 2016) (Petzinger, et al., 2015).  
Exercise plays a role in modulating the inflammatory response 
in the Parkinson’s diseased brain. It is well known that exercise 
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reduces inflammation and oxidative stress (Shu, et al., 2014). 
One of the ways that physical activity reduces inflammation is 
by increasing anti-inflammatory cytokine interleukin 10. Exercise 
also increases interleukin 6 which usually acts as an inflammato-
ry substance, but in the case of exercise, its effects are anti-in-
flammatory. Interleukin 6 accomplishes its job by eliciting, “an 
anti-inflammatory response that includes increased expression of 
several factors including interleukin 10 and interleukin 1 receptor 
antagonists, and inhibition of factors such as tumor necrosis fac-
tor alpha (Petzingeret, et. al.  2013, p. 722).” In addition, exercise 
reduces the proliferation of astrocytes and microglia cells which 
secrete harmful inflammatory cytokines. Physical activity also may 
drive the conversion of activated microglia cells from M1 myeloid 
cells which secret harmful cytokines to M2 myeloid cells which 
helpful secret cytokines (Jakowec, et. al. 2016). This may mean that 
exercise not only reduces inflammation but also stimulates the 
development of a positive immune response.  
Exercise also increases the secretion of neuronal protec-
tive factors, which include brain-derived neurotrophic factor 
(BDNF), Galia cell-derived neurotrophic factor (GDNF) and hy-
poxia-inducible factor 1 alpha (HIF-1α). Both BDNF and GDNF 
promote neuronal growth, prevent neuronal death and help 
the neurons function properly (Paillard, Ronlland, & Barreto, 
2015) (Morgan, Corrigan, & Baune, 2015). BDNF, in particular, 
is activated by aerobic exercise and has been found to reduce 
rigidity and muscle stiffness (Morgan, Corrigan, & Baune, 2015) 
(Jakowec, Wang, Holschneider, Beeler, & Petzinger, 2016). Skilled 
based exercise increases cortical-striatal function, which results 
in an increased demand for oxygen. The lack of oxygen activates 
transcription factor HIF-1α. This transcription factor increases 
neuronal health by regulating genes that control, “Metabolism, 
mitochondrial integrity … and signaling cascade pathways in-
volved in nitric oxide synthase and glutamine synaptogenesis 
(Jakowec, Wang, Holschneider, Beeler, & Petzinger, 2016, p. 41).” 
Thus, both aerobic and skill-based exercise help increase the 
release of neuroprotective factors.
Conclusion
Parkinson’s Disease is the second most common neurodegen-
erative disease, and its prevalence is expected to double by 2040 
(Ridgel, et. al. 2015). There is no cure for Parkinson’s Disease. All 
the available mainstream treatments cause adverse side effects 
and are only successful at eliminating a small number of symp-
toms. However, alternative therapies such as exercise have been 
found to reduce targeted symptoms, without causing negative 
side effects. Unfortunately, exercise therapy although growing in 
popularity is not being used by most primary doctors to treat 
Parkinson’s Disease. Educating affected individuals and medical 
practitioners on the benefits of exercise programs can poten-
tially help improve the lives of many individuals. Why should 
medications that cause a plethora of side effects be prescribed 
when we can use exercise programs instead? Why tell patients 
that there is no hope in sight for them, when in fact exercise 
can potentially stop the progression of Parkinson’s disease and 
in some cases eliminate all Parkinson’s disease symptoms. It 
is time for medical professionals to change their outlook on 
Parkinson’s Disease, instead of relaying a message of helpless-
ness they should relay a message of hope.
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